FIGURE 17. Deterministic base-case incremental cost–utility for ImR CML: cost–utility plane.

FIGURE 17Deterministic base-case incremental cost–utility for ImR CML: cost–utility plane

C-E, cost-effectiveness.

From: 5, Cost-effectiveness: chronic myeloid leukaemia in chronic phase

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.